HRP20010311A2 - Analgesic regimen - Google Patents
Analgesic regimen Download PDFInfo
- Publication number
- HRP20010311A2 HRP20010311A2 HR20010311A HRP20010311A HRP20010311A2 HR P20010311 A2 HRP20010311 A2 HR P20010311A2 HR 20010311 A HR20010311 A HR 20010311A HR P20010311 A HRP20010311 A HR P20010311A HR P20010311 A2 HRP20010311 A2 HR P20010311A2
- Authority
- HR
- Croatia
- Prior art keywords
- tramadol
- days
- day
- titration
- treatment
- Prior art date
Links
- 230000000202 analgesic effect Effects 0.000 title description 7
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 88
- 229960004380 tramadol Drugs 0.000 claims description 87
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 87
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims description 23
- 229960003107 tramadol hydrochloride Drugs 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 21
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 6
- 230000036592 analgesia Effects 0.000 claims 6
- 238000004448 titration Methods 0.000 description 47
- 230000000694 effects Effects 0.000 description 34
- 230000002411 adverse Effects 0.000 description 20
- 208000002193 Pain Diseases 0.000 description 17
- 206010028813 Nausea Diseases 0.000 description 16
- 206010047700 Vomiting Diseases 0.000 description 16
- 230000008693 nausea Effects 0.000 description 16
- 239000003814 drug Substances 0.000 description 14
- 230000008673 vomiting Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 208000000094 Chronic Pain Diseases 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 230000001186 cumulative effect Effects 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 208000002173 dizziness Diseases 0.000 description 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 208000012886 Vertigo Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 231100000889 vertigo Toxicity 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000013284 inhibition of norepinephrine uptake Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000697 serotonin reuptake Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- TVYLLZQTGLZFBW-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol Chemical group COC1=CC=CC(C2(O)C(CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- -1 mono-O Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 229940078987 tramadol hydrochloride 50 mg Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10656798P | 1998-11-02 | 1998-11-02 | |
| PCT/US1999/023513 WO2000025769A1 (en) | 1998-11-02 | 1999-10-12 | Analgesic regimen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20010311A2 true HRP20010311A2 (en) | 2002-06-30 |
Family
ID=22312128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20010311A HRP20010311A2 (en) | 1998-11-02 | 2001-05-02 | Analgesic regimen |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1126834A1 (ru) |
| CN (1) | CN1346266A (ru) |
| AR (1) | AR021054A1 (ru) |
| AU (1) | AU763273B2 (ru) |
| BR (1) | BR9914981A (ru) |
| CA (1) | CA2348907A1 (ru) |
| CZ (1) | CZ20011535A3 (ru) |
| EA (1) | EA003557B1 (ru) |
| HR (1) | HRP20010311A2 (ru) |
| HU (1) | HUP0104260A3 (ru) |
| NO (1) | NO20012133L (ru) |
| PL (1) | PL348808A1 (ru) |
| WO (1) | WO2000025769A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1905435A3 (en) * | 2003-03-11 | 2008-05-14 | Euro-Celtique S.A. | Titration dosing regimen for controlled release tramadol |
| US7413749B2 (en) * | 2003-03-11 | 2008-08-19 | Purdue Pharma L.P. | Titration dosing regimen for controlled release tramadol |
| US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
| JP2009507047A (ja) | 2005-09-09 | 2009-02-19 | ラボファーム インコーポレイテッド | 持続性薬物放出組成物 |
| CN109069483A (zh) * | 2016-02-29 | 2018-12-21 | 格吕伦塔尔有限公司 | 西博帕多的滴定 |
-
1999
- 1999-10-12 EP EP99951876A patent/EP1126834A1/en not_active Withdrawn
- 1999-10-12 CN CN99814987A patent/CN1346266A/zh active Pending
- 1999-10-12 PL PL99348808A patent/PL348808A1/xx not_active Application Discontinuation
- 1999-10-12 CA CA002348907A patent/CA2348907A1/en not_active Abandoned
- 1999-10-12 AU AU64224/99A patent/AU763273B2/en not_active Ceased
- 1999-10-12 WO PCT/US1999/023513 patent/WO2000025769A1/en not_active Application Discontinuation
- 1999-10-12 CZ CZ20011535A patent/CZ20011535A3/cs unknown
- 1999-10-12 EA EA200100501A patent/EA003557B1/ru not_active IP Right Cessation
- 1999-10-12 HU HU0104260A patent/HUP0104260A3/hu unknown
- 1999-10-12 BR BR9914981-8A patent/BR9914981A/pt not_active IP Right Cessation
- 1999-11-01 AR ARP990105524A patent/AR021054A1/es unknown
-
2001
- 2001-04-30 NO NO20012133A patent/NO20012133L/no not_active Application Discontinuation
- 2001-05-02 HR HR20010311A patent/HRP20010311A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA200100501A1 (ru) | 2001-10-22 |
| PL348808A1 (en) | 2002-06-17 |
| CZ20011535A3 (cs) | 2002-08-14 |
| CA2348907A1 (en) | 2000-05-11 |
| WO2000025769A1 (en) | 2000-05-11 |
| AU6422499A (en) | 2000-05-22 |
| EA003557B1 (ru) | 2003-06-26 |
| AR021054A1 (es) | 2002-06-12 |
| HUP0104260A3 (en) | 2002-11-28 |
| NO20012133D0 (no) | 2001-04-30 |
| EP1126834A1 (en) | 2001-08-29 |
| NO20012133L (no) | 2001-07-02 |
| HUP0104260A2 (en) | 2002-08-28 |
| BR9914981A (pt) | 2001-10-30 |
| AU763273B2 (en) | 2003-07-17 |
| CN1346266A (zh) | 2002-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6339105B1 (en) | Analgesic regimen | |
| Gibson | Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl | |
| US10653700B2 (en) | Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof | |
| JP3599750B2 (ja) | トラマドールとｎｍｄａの組合せによる痛み軽減法 | |
| JP2000508341A (ja) | 片頭痛の治療法及び薬効の強化組成物 | |
| UA55507C2 (ru) | Комбинации агонист / антагонист опиоида | |
| US20090312361A1 (en) | Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria | |
| JP2017506244A (ja) | ノルイボガイン及び関連化合物を用いた治療方法 | |
| CN111479592B (zh) | 阿片样物质使用障碍、阿片样物质戒断症状和慢性疼痛的治疗 | |
| JP2003520234A (ja) | 薬物中毒の治療方法 | |
| DK2405748T3 (en) | ADMINISTRATION OF INTRAVENOUS IBUPROFEN | |
| WO2007069925A2 (en) | Non-neurotoxic recreational drugs and a method of treating recreational drug abuse | |
| CZ60697A3 (cs) | Farmaceutický prostředek | |
| HRP20010311A2 (en) | Analgesic regimen | |
| Robinson | Buprenorphine-containing treatments: place in the management of opioid addiction | |
| Abel | Tramadol: an alternative analgesic to traditional opioids and NSAIDs | |
| CN116808038A (zh) | 阿片类物质和n-酰基乙醇胺的组合 | |
| Chow et al. | Dextromethorphan potentiates morphine antinociception at the spinal level in rats | |
| US20030199496A1 (en) | Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use | |
| MXPA01004414A (en) | Analgesic regimen | |
| EP4065123B1 (en) | Use of 2-phenyl-6-(1h-imidazol-1-yl) quinazoline for the prevention of abuse and of side effects of at least one opioid | |
| Williams | Tramadol hydrochloride: something new in oral analgesic therapy | |
| CZ2006623A3 (cs) | Kombinace deramciklanu a opioidů jako analgetik | |
| RU2213561C2 (ru) | Болеутоляющие композиции, содержащие ненаркотический анальгетик и усилитель анальгезии | |
| Wolf et al. | The N-Methyl-d-Aspartate Antagonist Dextrorphan Acts Like Ketamine by Selectively Increasing Tail Flick Lactencies in Spinally Transected But Not Intact Rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20010912 Year of fee payment: 3 |
|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| OBST | Application withdrawn |